• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Direct-acting antiviral treatment for hepatitis C.

作者信息

Holmes Jacinta A, Rutledge Stephanie M, Chung Raymond T

机构信息

Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA; Department of Gastroenterology, St Vincent's Hospital, University of Melbourne, Fitzroy, VIC, Australia.

Liver Center, Gastrointestinal Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.

DOI:10.1016/S0140-6736(18)32326-2
PMID:30765125
Abstract
摘要

相似文献

1
Direct-acting antiviral treatment for hepatitis C.丙型肝炎的直接抗病毒治疗
Lancet. 2019 Apr 6;393(10179):1392-1394. doi: 10.1016/S0140-6736(18)32326-2. Epub 2019 Feb 11.
2
[Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].直接作用抗病毒药物治疗慢性丙型肝炎病毒感染患者的有效性和安全性
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):175-178. doi: 10.3760/cma.j.issn.1007-3418.2018.03.004.
3
Antiviral drugs have made hepatitis C eminently treatable.
Manag Care. 2018 Nov;27(11):23-30.
4
[Selection of direct-acting antiviral agents for chronic hepatitis C infection].[慢性丙型肝炎感染直接抗病毒药物的选择]
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.
5
Concerns About Direct-Acting Antiviral Agents for Hepatitis C-Cause for Reassurance.对丙型肝炎直接抗病毒药物的担忧——令人安心的理由
JAMA Netw Open. 2019 Jun 5;2(6):e194757. doi: 10.1001/jamanetworkopen.2019.4757.
6
Editorial: hepatitis C direct acting antiviral agents and the kidney-authors' reply.社论：丙型肝炎直接抗病毒药物与肾脏——作者回复
Aliment Pharmacol Ther. 2017 Aug;46(3):379-380. doi: 10.1111/apt.14187.
7
New Direct-Acting Antiviral Agents Can Be Hepatotoxic in Patients With Hepatitis C Virus Infection and Decompensated Cirrhosis.新型直接抗病毒药物可能对丙型肝炎病毒感染且失代偿期肝硬化患者具有肝毒性。
Clin Gastroenterol Hepatol. 2016 Nov;14(11):1669-1671. doi: 10.1016/j.cgh.2016.06.009. Epub 2016 Jun 18.
8
Societal Perspectives and Patient/Public Involvement in Direct-Acting Antiviral Agent Coverage of Hepatitis C Treatment in the United States.
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1814-1815. doi: 10.1016/j.cgh.2017.06.009. Epub 2017 Jun 10.
9
Hepatitis C reinfection in prisons with broad access to Direct Acting Antiviral treatments.在广泛可获得直接抗病毒治疗的监狱中丙型肝炎再感染情况。
Int J Drug Policy. 2020 Mar;77:102597. doi: 10.1016/j.drugpo.2019.11.005. Epub 2020 Jan 15.
10
The Promise of Direct-Acting Antiviral Therapies to Improve Care and Outcomes in Patients With Cancer Who Have Chronic Hepatitis C Infection.
J Oncol Pract. 2019 Dec;15(12):639-640. doi: 10.1200/JOP.19.00664.

引用本文的文献

1
Long-Term Outcomes of Ledipasvir/Sofosbuvir Treatment in Hepatitis C: Viral Suppression, Hepatocellular Carcinoma, and Mortality in Mongolia.来迪派韦/索磷布韦治疗丙型肝炎的长期结果：蒙古的病毒抑制、肝细胞癌和死亡率
Viruses. 2025 May 22;17(6):743. doi: 10.3390/v17060743.
2
Advancing high-throughput anti-HCV drug screening: a novel dual-reporter HCV replicon model with real-time monitoring.推进高通量抗丙型肝炎病毒药物筛选：一种具有实时监测功能的新型双报告基因丙型肝炎病毒复制子模型。
Res Pharm Sci. 2025 Feb 20;20(1):41-54. doi: 10.4103/RPS.RPS_249_23. eCollection 2025 Feb.
3
Chronic Hepatitis C Virus Infection, Extrahepatic Disease and the Impact of New Direct-Acting Antivirals.
慢性丙型肝炎病毒感染、肝外疾病及新型直接抗病毒药物的影响
Pathogens. 2024 Apr 19;13(4):339. doi: 10.3390/pathogens13040339.
4
Evaluation of patients treated with direct-acting anti-viral therapy for chronic hepatitis C and their risk of hepatocellular carcinoma in Hong Kong.香港慢性丙型肝炎患者接受直接抗病毒治疗的疗效及其肝细胞癌风险评估。
BMC Gastroenterol. 2024 Jan 25;24(1):49. doi: 10.1186/s12876-023-03099-2.
5
Markers of Natural Killer Cell Exhaustion in HIV/HCV Coinfection and Their Dynamics After HCV Clearance Mediated by Direct-Acting Antivirals.HIV/HCV合并感染中自然杀伤细胞耗竭的标志物及其在直接作用抗病毒药物介导的HCV清除后的动态变化
Open Forum Infect Dis. 2023 Nov 22;10(12):ofad591. doi: 10.1093/ofid/ofad591. eCollection 2023 Dec.
6
ASPP2 binds to hepatitis C virus NS5A protein via an SH3 domain/PxxP motif-mediated interaction and potentiates infection.ASPP2 通过 SH3 结构域/PxxP 基序介导的相互作用与丙型肝炎病毒 NS5A 蛋白结合，并增强感染。
J Gen Virol. 2023 Sep;104(9). doi: 10.1099/jgv.0.001895.
7
A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants.一类新型广谱活性位点定向 3C 样蛋白酶抑制剂，对高度免疫逃逸的 SARS-CoV-2 奥密克戎亚变种具有纳摩尔抗病毒活性。
Emerg Microbes Infect. 2023 Dec;12(2):2246594. doi: 10.1080/22221751.2023.2246594.
8
Editorial: Effective Direct-Acting Antiviral Treatments Support Global and National Programs to Eliminate Hepatitis C.社论：有效的直接抗病毒治疗支持全球和国家消除丙型肝炎计划。
Med Sci Monit. 2023 Apr 1;29:e940519. doi: 10.12659/MSM.940519.
9
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection.评估机器学习算法在预测慢性丙型肝炎感染患者直接抗病毒治疗失败中的应用。
Sci Rep. 2022 Oct 27;12(1):18094. doi: 10.1038/s41598-022-22819-4.
10
Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis.当前用于评估肝病成本效益的健康效用评分的标准值：一项荟萃分析。
World J Gastroenterol. 2022 Aug 21;28(31):4442-4455. doi: 10.3748/wjg.v28.i31.4442.